Despite an increase in consolidation activity the CDMO sector remains fragmented. This creates a complex environment for drug developers making outsourcing decisions. Acquiring smaller companies gives companies access to sophisticated technologies and advances their capabilities, often making them a more attractive prospect for potential customers.
By acquiring new facilities, CDMOs can add new and complementary capabilities, increase capacity, and expand geographical reach.
Embarking upon M&A transactions allows companies to offer customers a sophisticated end-to-end solution for their project. As such, opportunities for consolidation are helping to positively shape the market.
Mark Quick, vice president of corporate development, at Recipharm spoke to GEN about the key advantages of M&A activity within the pharmaceutical sector and explores the capabilities and technologies it can offer companies.